Lawson obtains $4.4mn for adverse drug reaction prevention program
Date: 2018-02-27   Author: Dhananjay Punekar  Category: #news

Lawson obtains $4.4mn for adverse drug reaction prevention program

Lawson Health Research Institute, a London-headquartered hospital-based research institute, is likely to receive USD 4.4 million in the form of investments for conducting research on preventing adverse drug reactions. According to some of the key officials of the institute, adverse medicine reactions incur an expenditure of more than USD 5 billion per year for the healthcare sector in Canada. They further claimed that drug reactions are one of the leading causes of patient deaths in hospitals as well.

The institute states that over the past few years, biotechnology has made rapid advances where one can get results of DNA analysis on the same-day after conducting clinical trials. From the outcomes, doctors are now able to forecast whether a patient requires a high or low dose of a particular medicine.

Reportedly, researchers are of the view that genetic markers have proved beneficial not only for doctors but have also helped in saving the lives of numerous patients. As per reliable sources, the Ontario Research Fund, London Health Sciences Foundation, and Thermo Fisher Scientific have been providing funds to Lawson for each quarter of the year commencing from 2017. The funding is apparently expected to continue till next five years.

The head of the research group at Lawson has announced that the research & development study on adverse drug reactions will help in the expansion of its personalized medicine project over the next few years. The funding also aims to promote the application of personalized drugs in the pharmaceutical, biotechnology & healthcare sectors, as these medicines make use of the patient’s DNA to determine the effects of particular drugs on the patient’s immune system, skin, and other internal & external parts of the body.

For the record, the funding that Lawson’s research team has received will also be used to test many other drugs. It is being speculated that the investments have facilitated the institute to prescribe 5-fluorouracil for conducting clinical trials on cancer patients.



About Author


Dhananjay Punekar

Dhananjay Punekar

Dhananjay currently works as a content writer at AlgosOnline. A post graduate in mathematics as well as business administration, he worked as a process executive in Infosys BPO Limited before switching his professional genre. Following his childhood passion, he opted fo...

Read More

More from Dhananjay


Post Recommendents

Sprint & T-Mobile revise merger deal with an aim to close it by April
Author: Saipriya Iyer

T-Mobile, a renowned wireless network operator, and Sprint Corporation, an American telecommunication company, together announced that they have reached a new conclusion for their megamerger deal.

This should open ways for both companies...


Lyft returns with its shared e-bike rental program in New York City
Author: Pankaj Singh

Lyft, Inc. has reportedly announced the launch of several electric bikes across New York City for rent. This move comes 10 months after Lyft pulled its electric bikes from the market after receiving numerous injury rep...


Uber to close customer-support office in LA & shift base to Manila
Author: Saipriya Iyer

Uber Technologies Inc., a multinational ride-hailing company, has recently announced the closing of its Los Angeles office, reportedly laying off nearly 80 employees in the process. Without advance notice, the employee...